PHARMACEUTICAL COMPOUNDS

摘要

The invention provides a combination of a cytotoxic compound or signalling inhibitor and a compound having the formula (0): or salts or tautomers or N-oxides or solvates thereof; wherein X is a group R¹-A-NR⁴- or a 5- or 6-membered carbocyclic or heterocyclic ring; A is a bond, SO₂, C-O, NR^g(C-O) or 0(C-O) wherein R^g is hydrogen or C_1-4 hydrocarbyl optionally substituted by hydroxy or C_1-4alkoxy; Y is a bond or an alkylene chain of 1, 2 or 3 carbon atoms in length; R¹ is hydrogen; a carbocyclic or heterocyclic group having from 3 to 12 ring members; or a C_1-8hydrocarbyl group optionally substituted by one or more substituents selected from halogen (e.g. fluorine), hydroxy, C_1-4 hydrocarbyloxy, amino, mono- or di-C_1-4 hydrocarbylamino, and carbocyclic or heterocyclic groups having from 3 to 12 ring members, and wherein 1 or 2 of the carbon atoms of the hydrocarbyl group may optionally be replaced by an atom or group selected from O, S, NH, SO, SO₂; R² is hydrogen; halogen; C_1-4alkoxy (e.g. methoxy); or a C_1-4 hydrocarbyl group optionally substituted by halogen (e.g. fluorine), hydroxyl or C_1-4alkoxy (e.g. methoxy); R³ is selected from hydrogen and carbocyclic and heterocyclic groups having from 3 to 12 ring members; and R⁴ is hydrogen or a C_1-4 hydrocarbyl group optionally substituted by halogen (e.g. fluorine), hydroxyl or C_1-4 alkoxy (e.g. methoxy).